Skip to main content

IDWeek 2022 Main banner

Tweets by IDWeek 2022

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

398 Views

ViewAttendees 22

Session: New Antimicrobials and ID Diagnostics in the Pipeline - Bacterial

45 - ABX-01, a novel immunotherapy to treat Gram-negative infections

Thursday, October 20, 2022

8:00 AM – 8:10 AM US ET

Location: 145 AB

Watch the live stream on the conference website.

All relevant financial disclosures have been mitigated.

Speaker(s)

Helen Bright, PhD (she/her/hers)

VP of R&D
Centauri Therapeutics
Cheshire, England, United Kingdom

Disclosure: Disclosure(s): Medimmune/AstraZeneca: Employee (Terminated), Stocks/Bonds (Terminated)

Disclosure(s):

Helen Bright, PhD: Medimmune/AstraZeneca: Employee (Terminated), Stocks/Bonds (Terminated)